Non-Invasive Ventilation for Acute Respiratory Distress Syndrome

(WINDSURFER Trial)

This trial explores the best way to provide non-invasive respiratory support for adults in the emergency department with acute hypoxemic respiratory failure, a serious condition where blood oxygen levels drop dangerously low. The trial compares two methods: Non-Invasive Positive Pressure Ventilation (NIPPV), which delivers oxygen under pressure through a face mask, and High-Flow Nasal Oxygen (HFNO), which provides oxygen through a special nasal tube. Researchers will examine how these methods affect survival, the need for more intense breathing assistance, and the duration of support required. Individuals experiencing breathing difficulties and requiring urgent oxygen support might qualify for this study. As an unphased trial, this study offers patients the opportunity to contribute to vital research that could enhance emergency respiratory care.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have shown that High-Flow Nasal Oxygen (HFNO) is safe for people with breathing problems. Research indicates that HFNO can ease breathing distress and reduce the need for more invasive treatments. Most people tolerate it well, and serious side effects are rare.

Similarly, Non-Invasive Positive Pressure Ventilation (NIPPV) is considered safe for treating breathing issues. Studies have found that NIPPV can help avoid the need for a breathing tube. Most people handle it without major problems, although it might not work for everyone.

Researchers are excited about these treatments for Acute Respiratory Distress Syndrome (ARDS) because they offer non-invasive alternatives to traditional mechanical ventilation. High-Flow Nasal Oxygen (HFNO) delivers humidified oxygen through a nasal cannula, providing comfort and ease of use compared to intubation. On the other hand, Non-Invasive Positive Pressure Ventilation (NIPPV) uses a face mask to assist breathing, which might reduce the risk of complications associated with invasive procedures. Both methods aim to improve oxygenation without the need for sedation or an endotracheal tube, potentially leading to quicker recovery times and less hospital resource use.

This trial will compare High-Flow Nasal Oxygen (HFNO) with Non-Invasive Positive Pressure Ventilation (NIPPV) for patients experiencing acute hypoxemic respiratory failure. Studies have shown that HFNO effectively reduces the need for intubation, where a tube is inserted to assist breathing, in patients with low oxygen levels. It often leads to quicker improvement in breathing and comfort. Research indicates that HFNO helps prevent further breathing problems and is generally well tolerated by patients. Meanwhile, NIPPV has been found to lower death rates and shorten hospital stays when used early in patients with sudden lung injury or breathing failure. Evidence suggests that NIPPV helps avoid the need for more invasive breathing support. Both treatments show promising results in improving patient survival and reducing the severity of breathing issues.¹⁶⁷⁸⁹